Smith Ah, Hardison Dc, Bridges Bc, Pietsch Jb
Division of Pediatric Critical Care Medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt and Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Perfusion. 2013 Jan;28(1):54-60. doi: 10.1177/0267659112457969. Epub 2012 Aug 14.
Red blood cell (RBC) transfusion is used in the critically ill with low hemoglobin concentrations to optimize oxygen utilization and delivery imbalance. Data suggest that RBC transfusion is also independently associated with significant morbidity. We seek to characterize RBC transfusion volumes among patients receiving extracorporeal membrane oxygenation (ECMO) support and test the hypothesis that red blood cell transfusion volume is an independent risk factor for mortality.
Records of all patients receiving ECMO support from 2001 through 2010 at a university-affiliated children's hospital were retrospectively reviewed.
Among 484 ECMO runs reviewed, indications for ECMO were classified as cardiac (40%), non-cardiac (42%) or institution of ECMO during cardiopulmonary resuscitation (CPR) (18%). Median duration of ECMO support was 4.6 days, with overall survival to hospital discharge significantly higher among non-cardiac patients (60%) relative to patients supported for cardiac (37%) or external CPR (ECPR) indications (34%, p<0.001). Median RBC transfusion volumes with respect to ECMO indication were significantly greater among cardiac (105 mL/kg/day ECMO) and ECPR patients (66 mL/kg/day ECMO) relative to patients supported for non-cardiac indications (20 mL/kg/day ECMO, p<0.001). Among patients supported with ECMO for non-cardiac indications alone (n=203), independent of covariates, including weight, venoarterial mode of ECMO support, presence of congenital diaphragmatic hernia and complications, including hemorrhage, neurologic injury, and renal insufficiency, each RBC transfusion volume of 10 mL/kg/day ECMO was associated with a 24% increase in the odds of in-hospital mortality (OR 1.024, 95% CI 1.004-1.046, p=0.018).
Greater red blood cell transfusion volumes among patients supported with ECMO for non-cardiac indications are independently associated with an increase in odds of mortality. A prospective investigation of restrictive RBC transfusion practices while receiving ECMO may be warranted in this population.
红细胞(RBC)输注用于血红蛋白浓度低的危重症患者,以优化氧利用和输送失衡。数据表明,红细胞输注还与显著的发病率独立相关。我们旨在描述接受体外膜肺氧合(ECMO)支持的患者的红细胞输注量,并检验红细胞输注量是死亡率独立危险因素这一假设。
回顾性分析了2001年至2010年在一所大学附属医院接受ECMO支持的所有患者的记录。
在回顾的484例ECMO治疗中,ECMO的适应证分为心脏疾病(40%)、非心脏疾病(42%)或心肺复苏(CPR)期间启动ECMO(18%)。ECMO支持的中位持续时间为4.6天,非心脏疾病患者的出院总体生存率(60%)显著高于因心脏疾病(37%)或体外心肺复苏(ECPR)适应证接受支持的患者(34%,p<0.001)。相对于非心脏疾病适应证患者(20 mL/kg/天ECMO),心脏疾病患者(105 mL/kg/天ECMO)和ECPR患者(66 mL/kg/天ECMO)的红细胞输注量中位数在ECMO适应证方面显著更高(p<0.001)。在仅因非心脏疾病适应证接受ECMO支持的患者(n=203)中,独立于协变量,包括体重、ECMO支持的静脉-动脉模式、先天性膈疝的存在以及并发症,包括出血、神经损伤和肾功能不全,每10 mL/kg/天ECMO的红细胞输注量与住院死亡率增加24%相关(OR 1.024,95% CI 1.004-1.046,p=0.018)。
因非心脏疾病适应证接受ECMO支持的患者中,更高的红细胞输注量与死亡率增加独立相关。对于这一人群,在接受ECMO时对限制性红细胞输注实践进行前瞻性研究可能是必要的。